Abstract

Background: The study investigates the expression of Carbonic Anhydrase-II (CA-II) antibodies in both blood and tissue samples to understand their systemic and local effects. Objective: The research aims to identify effective dosages and assess the differences in antibody levels across various treatment groups of undescended testes Sprague Dawley model. To measure and compare the levels of CA-II antibodies in blood and tissue samples, determine the most effective dosage for reducing tissue CA-II levels, and analyze the systemic versus local impacts of these antibodies. Methods: The study employed immunohistochemistry to assess CA-II antibody expression in undescended testes model of Sprague Dawley tissue and blood, with brown-colored cells indicating positive expression. Levene’s test confirmed homogeneity of variance (p=0.660), allowing for ANOVA to identify significant differences in CA-II levels among groups (p=0.000). Tukey’s post hoc test was used to pinpoint specific group differences. Results: The analysis revealed significant differences in CA-II expression between groups. The dosage of 10 mg/KgBB was found to be most effective in reducing tissue CA-II levels. Blood CA-II concentrations were consistently higher than tissue levels across all groups, indicating a strong systemic presence. Conclusion: The study highlights the significant distinctions in CA-II antibody levels between blood and tissue samples. It underscores the importance of dosage in managing CA-II levels and the need to consider both systemic and local impacts in clinical settings. These findings provide a basis for future research into targeted therapies for conditions mediated by CA-II.

Key words: CA-II antibodies, immunohistochemistry, blood and tissue samples.